Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspirin use in MI patients

This article was originally published in The Tan Sheet

Executive Summary

"There is a marked underutilization of aspirin in older patients with documented Q-wave myocardial infarction at the time of admission to a nursing home," concludes Wilbert Aronow, MD, Hebrew Hospital Home, Bronx, N.Y. in the May issue of the Journal of the American Geriatric Society. Only 60 of 350 MI patients (17%) were receiving aspirin at the time they were admitted, the researcher notes. Subjects were patients 60 and older with documented MI and no contraindications to aspirin use at the time study; 231 women and 119 men were examined. Pointing to the benefits of aspirin administration (reduced risk of recurrent MI, stroke, vascular death, reduced cardiac mortality), the researcher notes the American College of Cardiology/American Heart Association guidelines advise use of 160-325 mg aspirin upon experiencing acute MI and indefinitely thereafter unless specifically contraindicated...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel